HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Mario Sznol Selected Research

3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)

1/2008A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
9/2007Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
7/2006Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
10/2004A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
5/2004Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
12/2003Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
9/2003Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Mario Sznol Research Topics

Disease

36Neoplasms (Cancer)
08/2015 - 01/2002
35Melanoma (Melanoma, Malignant)
09/2015 - 01/2002
6Leukemia
01/2008 - 12/2003
5Neoplasm Metastasis (Metastasis)
03/2015 - 05/2012
3Renal Cell Carcinoma (Grawitz Tumor)
09/2008 - 01/2002
2Fatigue
04/2015 - 05/2012
2Thrombocytopenia (Thrombopenia)
04/2015 - 01/2002
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2014 - 06/2012
2Colitis
10/2013 - 07/2006
2Body Weight (Weight, Body)
07/2013 - 06/2012
2Hematologic Neoplasms (Hematological Malignancy)
09/2007 - 12/2003
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2006 - 05/2004
2Hyperbilirubinemia
07/2006 - 01/2002
1Disease Progression
07/2015
1Neutropenia
04/2015
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
04/2015
1Graft vs Host Disease (Graft-Versus-Host Disease)
01/2015
1Ulcer
10/2013
1Lymphocytosis
10/2013
1Lung Neoplasms (Lung Cancer)
03/2013
1Prostatic Neoplasms (Prostate Cancer)
06/2012
1Colorectal Neoplasms (Colorectal Cancer)
06/2012
1Inflammation
05/2012
1Dehydration (Water Stress)
05/2012
1Exanthema (Rash)
05/2012
1Asthma (Bronchial Asthma)
05/2012
1Lung Injury
05/2012
1Testicular Neoplasms (Testicular Cancer)
10/2011
1Hypotension (Low Blood Pressure)
07/2008
1Kidney Neoplasms (Kidney Cancer)
07/2008

Drug/Important Bio-Agent (IBA)

9ipilimumabIBA
07/2015 - 10/2011
9AntibodiesIBA
06/2015 - 07/2005
7Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
01/2008 - 07/2003
73-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA
01/2008 - 09/2003
6AntigensIBA
04/2014 - 09/2009
5Biological Markers (Surrogate Marker)IBA
05/2011 - 01/2009
5Phosphotransferases (Kinase)IBA
05/2011 - 12/2005
4cytotoxic T-lymphocyte antigen 4IBA
07/2015 - 10/2011
3Immunoglobulins (Immunoglobulin)IBA
06/2015 - 11/2014
3Interleukin-2 (IL2)IBA
04/2011 - 07/2008
3laromustine (VNP40101M)IBA
11/2005 - 05/2004
3VNP 20009 (VNP20009)IBA
07/2005 - 01/2002
2Carbon MonoxideIBA
09/2015 - 04/2012
2ChitinaseIBA
02/2015 - 05/2012
2Carboplatin (JM8)FDA LinkGeneric
05/2013 - 01/2007
2Proteins (Proteins, Gene)IBA
05/2012 - 04/2011
2Cancer VaccinesIBA
04/2012 - 01/2007
2VaccinesIBA
10/2011 - 01/2007
2PLX4032IBA
04/2010 - 01/2010
2InterferonsIBA
01/2010 - 12/2005
2DNA (Deoxyribonucleic Acid)IBA
01/2009 - 12/2003
2Cytarabine (Cytosar-U)FDA LinkGeneric
07/2006 - 11/2005
1Lipase (Acid Lipase)FDA Link
04/2015
1Alanine Transaminase (SGPT)IBA
04/2015
1Immunoglobulin G (IgG)IBA
04/2015
1Uveal melanomaIBA
03/2015
1Semaphorins (Semaphorin)IBA
02/2015
1plexinIBA
02/2015
1monomethyl auristatin EIBA
11/2014
1Glycoproteins (Glycoprotein)IBA
11/2014
1glembatumumab vedotinIBA
11/2014
1Monoclonal AntibodiesIBA
04/2014
1Messenger RNA (mRNA)IBA
01/2014
1temozolomide (Temodar)FDA LinkGeneric
05/2013
1Dacarbazine (DIC)FDA LinkGeneric
05/2013
1Paclitaxel (Taxol)FDA LinkGeneric
05/2013
1fotemustine (Muphoran)IBA
05/2013
1Phosphoprotein Phosphatases (Phosphatases, Protein)IBA
09/2012
1Serine (L-Serine)FDA Link
09/2012
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
05/2012
1CytokinesIBA
04/2012
1MicroRNAs (MicroRNA)IBA
06/2011
1RNA (Ribonucleic Acid)IBA
06/2011
1tyrosine receptor (receptor, tyrosine)IBA
05/2011
1src-Family KinasesIBA
05/2011
1dasatinib (BMS 354825)FDA Link
05/2011
1Carcinoembryonic AntigenIBA
04/2011
1OsteopontinIBA
04/2011
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
04/2011
1Tissue Inhibitor of Metalloproteinase-1IBA
04/2011
1Growth Differentiation Factor 15IBA
04/2011
1Small Interfering RNA (siRNA)IBA
09/2009
1Protein Kinases (Protein Kinase)IBA
09/2009
1bortezomib (Velcade)FDA Link
01/2009
1decitabine (5-aza-2'-deoxycytidine)FDA Link
01/2009
1Proteasome Endopeptidase Complex (Proteasome)IBA
01/2009
1First StepIBA
09/2008
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
09/2008
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2008
1glucuronyl glucosamine glycan sulfate (Vessel)IBA
09/2008
1fludarabineIBA
01/2008

Therapy/Procedure

9Immunotherapy
08/2015 - 12/2004
4Drug Therapy (Chemotherapy)
04/2015 - 07/2003
2Aftercare (After-Treatment)
04/2014 - 09/2003
2Intravenous Infusions
12/2003 - 01/2002
1Transplants (Transplant)
01/2015
1Stem Cell Transplantation
01/2015
1Colectomy
10/2013
1Castration
06/2012
1Tissue Therapy (Cell Therapy)
04/2011